Whether anti-PD-L1 mAb could affect Treg function remains unknown, but it might be a better choice than PD-1 blockade since PD-L1 is expressed on tumour cells while PD-1 is expressed on immune cells. This evidence concerns the gene CD274 and neoplasm.